| 1 |
Yang HM, Kim HS, Park KW, et al. Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling. Circulation 2004;110:301-8.
DOI
ScienceOn
|
| 2 |
Burklow J, Ralbovsky D. NIH Halts Use of COX-2 Inhibitor in Large Cancer Prevention Trial. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health;2004.
|
| 3 |
Wilner KD, Rushing M, Walden C, et al. Celecoxib does not affect the antiplatelet acitivey of aspirin in healthy volunteers. J Clin Pharmacol 2002;42:1027-30.
DOI
|
| 4 |
Chenevard R, Hurlimann D, Bechir M, et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003;107:405-9.
DOI
ScienceOn
|
| 5 |
Whelton A, White WB, Bello AE, Puma JA, Fort JG. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002;90:959-63.
DOI
ScienceOn
|
| 6 |
Altman R, Luciardi HL, Muntaner J, et al. Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study. Circulation 2002;106:191-5.
DOI
ScienceOn
|
| 7 |
Lee W, Suh JW, Yang HM, et al. Celecoxib does not attenuate the antiplatelet effects of aspirin and clopidogrel in healthy volunteers. Korean Circ J 2010;40:321-7.
DOI
ScienceOn
|
| 8 |
Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004;364:665-74.
DOI
|
| 9 |
Abelson R, Gardiner H. Pfizer warns of risks from its painkiller. The New York Times 2004:B1.
|
| 10 |
ADAPT Group. Cardiovasucalr and cerebrovascular events in the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). PLoS Clin Trials 2006;1:e33.
DOI
|
| 11 |
Kimmel SE, Berlin JA, Reilly M, et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005;142:157-64.
DOI
ScienceOn
|
| 12 |
Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8.
DOI
ScienceOn
|
| 13 |
Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: arandomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284:1247-55.
DOI
ScienceOn
|
| 14 |
Fitzgerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase- 2. N Engl J Med 2001;345:433-42.
DOI
ScienceOn
|
| 15 |
Wang K, Tarakji K, Zhou Z, et al. Celecoxib, a selective cyclooxygenase- 2 inhibitor, decreases monocyte chemoattractant protein-1 expression and neointimal hyperplasia in the rabbit atherosclerotic balloon injury model. J Cardiovasc Pharmacol 2005;45:61-7.
DOI
ScienceOn
|
| 16 |
Renda G, Tacconelli S, Capone ML, et al. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin Pharmacol Ther 2006;80-264-74.
DOI
ScienceOn
|
webmaster
